RLX has been shown to boost gene promoters controlled by the ER subtype, which protects against tumor development in response to estrogen, and hence has anti-tumor effect in breast cancer cells (Kim et al., 2015; Aldawsari et al., 2021). Here, ESR1 is linked to breast cancer.